A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer

被引：0
|
作者：
Harada, D. [1 ]
Kozuki, T. [1 ]
Nogami, N. [1 ]
Hotta, K. [2 ]
Aoe, K. [3 ]
Ohashi, K. [2 ]
Ninomiya, K. [2 ]
Hirata, T. [4 ]
Hinotsu, S. [5 ]
Toyooka, S. [6 ]
Kiura, K. [2 ]
机构：
[1] Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Yamaguchi Ube Med Ctr, Dept Med Oncol, Ube, Yamaguchi, Japan
[4] Kure Med Ctr, Dept Med Oncol, Kure, Japan
[5] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[6] Okayama Univ, Grad Sch Med, Gen Thorac Surg & Breast & Endocrinol Surg, Okayama, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; HER2; T-DM1;
D O I：
10.1016/j.jtho.2017.09.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 07.11
引用
收藏
页码：S1829 / S1829
页数：1
相关论文
共 50 条
  • [31] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [32] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Véronique Diéras
    Thomas Bachelot
    Targeted Oncology, 2014, 9 : 111 - 122
  • [33] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [34] The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer
    Dieras, Veronique
    Bachelot, Thomas
    TARGETED ONCOLOGY, 2014, 9 (02) : 111 - 122
  • [35] Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer.
    Yamashita-Kashima, Yoriko
    Fujimura, Takaaki
    Shu, Sei
    Yanagisawa, Mieko
    Mochizuki, Marie
    Yorozu, Keigo
    Kouno, Mirei
    Furugaki, Koh
    Higuchi, Ryota
    Shoda, Junichi
    Harada, Naoki
    Yoshimura, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [36] Phase 1 study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with normal or reduced hepatic function
    Li, Chunze
    Agarwal, Priya
    Dent, Susan
    Goncalves, Anthony
    Yi, Joo-Hee
    Strasak, Alexander
    Green, Marjorie
    Girish, Sandhya
    LoRusso, Pat
    CANCER RESEARCH, 2015, 75
  • [37] Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer
    Elias, A.
    Modi, S.
    Krop, I. E.
    Pegram, M.
    Ipe, D.
    Guardino, E. A.
    Althaus, B.
    LoRusso, P. L.
    CANCER RESEARCH, 2013, 73
  • [38] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer
    Xia, Yang
    Huang, Xiu
    Jin, Rui
    Li, Wen
    Shen, Huahao
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [40] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
12345